🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Postoperative Hypoxemia Increases the Risk of Anastomotic Leak After Radical Esophagectomy

Recruitingn/aAges 18 Years - 80 YearsAllSun Yat-sen University
NCT07309991 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to determine whether postoperative hypoxia (arterial partial pressure of oxygen (PaO₂)\<80 mmHg) is an independent risk factor for anastomotic leakage after esophagectomy. The investigators conducted a retrospective analysis of cases from their center over the past five years, stratifying patients into Low Pa0₂ Group and Normal Pa0₂ Group based on postoperative oxygen levels and comparing the incidence of anastomotic leakage between the groups. The goal is to establish whether hypoxia is a causative risk factor and whether correcting it can reduce the risk of anastomotic leakage.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients diagnosed with esophageal carcinoma or benign esophageal tumors * Patients requiring surgical resection of the lesion with subsequent esophageal reconstruction * Patients must have had at least one postoperative arterial blood gas analysis * Patients must have routinely undergone at least one of the following for postoperative evaluation of the anastomosis: endoscopy, CT scan, or esophagram Exclusion Criteria: * Patients who did not require esophageal reconstruction * Patients undergoing esophageal replacement with colon * Patients with incomplete data
💊

What it tests

  • Not listed
📍

Where

6 sites
Department of Thoracic Surgery, Sun Yat-sen University Cancer Center
Guangzhou, China
Cancer Hospital of Shantou University Medical College
Shantou, China
The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital
Shijiazhuang, China
Shanghai Chest Hospital
Shanghai, China
Sichuan Cancer Hospital
Chengdu, China
0817-2598459
Nanchong, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy